Bedaquiline (as part of longer regimens)
Treatment for Extensively Drug Resistant Tuberculosis
Typical Dosage: 400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Effectiveness
80%
Safety Score
50%
Clinical Trials
25
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Time to Effect
3-6 months
Treatment Duration
6 months (within 18-24 month regimen)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$7,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$9,333
Cost per Remission
$9,333
Comparison vs Older XDR-TB regimens without Bedaquiline
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Bedaquiline (as part of longer regimens) Outcomes
for Extensively Drug Resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+15%
Nausea
+18%
Arthralgia
+12%
Hepatotoxicity
+7%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov